Anti‐angiogenic therapy showed no clear difference in overall survival ( compared with no anti‐angiogenic therapy (high certainty).
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
Hysterectomy (simple or radical) with radiotherapy showed no clear difference in overall survival Median compared with radiotherapy alone (low certainty).
Hysterectomy (radical) with neoadjuvant chemotherapy showed no clear difference in overall survival Median compared with chemoradiotherapy alone (moderate certainty).
It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes overall survival Median compared with chemoradiotherapy alone (very low certainty).
Hysterectomy (simple or radical) with chemoradiotherapy showed no clear difference in overall survival Median compared with internal radiotherapy (brachytherapy) with chemoradiotherapy (low certainty).
It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).
Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Hysterectomy (simple or radical) with neoadjuvant chemotherapy probably leads to lower overall survival Median compared with radiotherapy alone (moderate certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).
Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).